The FDA formally removed semaglutide from its drug shortage list in early 2025, which triggered a compliance clock for compounding pharmacies to stop making copies. Deadlines have shifted due to ongoing litigation, but the trajectory is clear: compounded sema access is narrowing. A few things worth actually separating out here: The cost gap is not trivial. Compounded versions were running $100-200/month at some pharmacies vs $900-1000+ out of pocket for branded Wegovy. For anyone w/o solid coverage, that delta is not a minor inconvenience, it’s the whole ballgame. The bioequivalence situation is messier than either camp wants to admit. Compounders aren’t required to demonstrate equivalent PK to the reference product. The trial data we rely on (SUSTAIN series, STEP trials) is specifically Novo’s formulation and manufacturing process. Whether compounded versions deliver identical absorption profile is not well characterized. Not saying they don’t work, just that “it’s semaglutide” is doing a lot of work in that assumption. The shortage delisting doesn’t mean supply matches demand. It means FDA is satisfied based on manufacturer reporting and their internal methodology. That’s a different claim, and there’s historically meaningful lag between a formal delisting and real-world pharmacy availability. Legal status is still live. Several compounders got temporary injunctions. This is not settled. For the million-plus patients who switched to compounded versions specifically bc of cost, the access picture depends heavily on how the litigation resolves in the next few months
the bioequivalence data gap is fair. but real-world outcomes (side effect timelines, weight loss patterns, plateaus) track SUSTAIN closely, which suggests absorption is probably fine. “we don’t have formal studies” is getting mixed up with “this might not work,” and they’re different problems.
Brynn, the distinction you’re drawing is genuinely useful, but “outcomes track SUSTAIN closely” is still using informal observation as a proxy for the PK data we don’t have. Side effect timelines and weight loss patterns are clinical endpoints, not absorption measurements, and using the former as evidence of the latter is exactly the inferential gap worth naming.
delayed absorption would show in shifted side effect timelines, but i’m not seeing that - nausea week 1, appetite suppression early, plateau right on schedule. that’s not proof of bioequivalence, but it’s enough for the practical call. if compounded versions diverged materially, weight loss patterns wouldn’t track SUSTAIN the way they do. for people choosing $100/month vs unaffordable, that gap doesn’t need a formal study. fwiw.